Completed

A Phase II Study of Temozolomide, Thalidomide, and Lomustine in the Treatment of Advanced Melanoma

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

lomustine

+ temozolomide

+ thalidomide

Drug
Who is being recruted

Eye Diseases+14

+ Eye Neoplasms

+ Neoplasms

Over 18 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: July 2003
See protocol details

Summary

Principal SponsorMemorial Sloan Kettering Cancer Center
Last updated: January 18, 2013
Sourced from a government-validated database.Claim as a partner

Study start date: July 1, 2003

Actual date on which the first participant was enrolled.

OBJECTIVES: Primary Determine the antitumor activity of temozolomide, thalidomide, and lomustine, in terms of objective response rate, in patients with unresectable stage III or stage IV melanoma. Secondary Determine the toxicity profile of this regimen in these patients. Determine the duration of response and overall survival of patients treated with this regimen. OUTLINE: Patients receive oral temozolomide on days 1-42, oral thalidomide on days 1-56, and oral lomustine on days 1 and 29. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study within 2 years.

NCT00072345
Principal SponsorMemorial Sloan Kettering Cancer Center
Last updated: January 18, 2013
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Eye DiseasesEye NeoplasmsNeoplasmsNeoplasms by Histologic TypeNeoplasms by SiteNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve TissueSkin DiseasesSkin NeoplasmsUveal DiseasesUveal NeoplasmsSkin and Connective Tissue DiseasesNeuroectodermal TumorsNevi and MelanomasNeuroendocrine TumorsUveal MelanomaMelanoma

Criteria

DISEASE CHARACTERISTICS: Histologically confirmed metastatic malignant melanoma Unresectable stage III OR stage IV disease Ocular, mucosal, and cutaneous melanoma allowed Measurable disease Indicator lesions within a prior radiotherapy field must have recent evidence of disease progression Indicator lesions must be distinct from the surgical and/or radiation changes induced by prior local therapies No more than 2 symptomatic hemorrhagic lesions in the brain No hemorrhagic lesion(s) greater than 1 cm in diameter PATIENT CHARACTERISTICS: Age 18 and over Performance status Karnofsky 80-100% Life expectancy Not specified Hematopoietic Absolute granulocyte count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic Bilirubin no greater than 2 times upper limit of normal (ULN) SGOT and SGPT no greater than 2 times ULN Alkaline phosphatase no greater than 2 times ULN Lactic dehydrogenase no greater than 2 times ULN Renal Creatinine no greater than 2 mg/dL Cardiovascular No history of severe cardiovascular disease No myocardial infarction within the past 6 months No unstable angina No New York Heart Association class III or IV congestive heart failure No ventricular arrhythmia No uncontrolled arrhythmia Gastrointestinal No frequent vomiting No other medical condition that would preclude oral medication intake (e.g., partial bowel obstruction) Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective barrier contraception during and for 4 weeks after study participation HIV negative No AIDS-related illness No serious infection requiring IV antibiotics No other uncontrolled medical illness that would preclude study participation No other malignancy within the past 2 years except nonmelanoma skin cancer, carcinoma in situ of the cervix, or T1a or b prostate cancer meeting all of the following criteria: Detected incidentally at transurethral resection of the prostate (TURP) Comprises less than 5% of resected tissue Prostate-specific antigen normal since TURP PRIOR CONCURRENT THERAPY: Biologic therapy At least 3 weeks since prior immunotherapy or biologic therapy No concurrent immunotherapy Chemotherapy No prior systemic chemotherapy for melanoma No other concurrent chemotherapy Endocrine therapy Not specified Radiotherapy See Disease Characteristics At least 3 weeks since prior focused radiotherapy for brain metastases At least 3 weeks since prior radiosurgery At least 4 weeks since prior whole brain radiotherapy At least 3 weeks since prior interstitial brachytherapy No concurrent radiotherapy Surgery See Disease Characteristics At least 3 weeks since prior surgery for brain metastases At least 3 weeks since prior surgery requiring general anesthesia Other Recovered from all prior therapies

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Memorial Sloan-Kettering Cancer Center

New York, United StatesOpen Memorial Sloan-Kettering Cancer Center in Google Maps
CompletedOne Study Center